ERBB2 and breast cancer: Recently, a new CAR molecule targeting tMUC1, known as huMNC2-CAR44, has been activated in a clinical trial recruiting 69 (HER2-positive, HER2-negative, triple-negative) BC patients; the estimated study completion date is 15 January 2035 (NCT04020575).